Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States

INTRODUCTION: Perioperative (neoadjuvant and adjuvant) pembrolizumab has shown favorable efficacy in patients with early-stage non-small cell lung cancer (NSCLC). This study aims to evaluate the cost-effectiveness of this treatment from the perspective of the United States healthcare payers. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Wentao, Niu, Lishui, Wang, Ziqi, Lu, Ruoyu, Xiao, Gang, Deng, Fuxing, Tanzhu, Guilong, Zhou, Rongrong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562534/
https://www.ncbi.nlm.nih.gov/pubmed/37822936
http://dx.doi.org/10.3389/fimmu.2023.1268070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562534/
https://www.ncbi.nlm.nih.gov/pubmed/37822936
http://dx.doi.org/10.3389/fimmu.2023.1268070

Ejemplares similares